Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

32.54 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2
...
25 26 27 28 29 30 31 32 Next >
News headline image
Pfizer Stock Jumps After Diabetes Drug Tops Ozempic In Weight Loss ↗
Pfizer's diabetes drug led to faster weight loss than Novo Nordisk's Ozempic. 
Via Investor's Business Daily
News headline image
Intercept Crashes As FDA Advisors Deliver The Likely Deathblow For Its Highly Watched NASH Drug ↗
The FDA's advisors voted resoundingly against accelerated approval for obeticholic acid. 
Via Investor's Business Daily
News headline image
Hero or Zero? 3 High-Risk Biotech Stocks to Make You Rich … or Broke. ↗
These biotech companies are swinging for the fences. They may hit homers, they may strike out. But you'll definitely want to watch them. 
Via InvestorPlace
News headline image
7 Stocks That Wall Street Analysts Are Loving in May ↗
Though not perfect, an analyst rating can indicate where institutional investor sentiment lies; here are seven stocks that analysts love. 
Via InvestorPlace
News headline image
Why Viking Therapeutics Stock Is Buckling Today ↗
The biotech's shares can't escape the broader downward trend among its peer group today. 
Via The Motley Fool
News headline image
What 17 Analyst Ratings Have To Say About Viking Therapeutics ↗
 
Via Benzinga
News headline image
Why Viking Therapeutics Stock Bolted Higher Today ↗
The biotech's midstage NASH candidate passed another key hurdle. 
Via The Motley Fool
News headline image
Why Viking Therapeutics Stock Wobbled Today ↗
The biotech's shares dipped along with the broader markets in early-morning trading today. 
Via The Motley Fool
News headline image
Why Viking Therapeutics Stock Briefly Popped Today ↗
The biotech's shares rose briefly this morning following a sizable price target revision by an investing firm. 
Via The Motley Fool
News headline image
Viking Therapeutics Outperforms Expectations: Analyst Increases Price Target Following Successful VK2809 Trial ↗
Ligand Pharmaceuticals Incorporated's (NASDAQ: LGND) partner Viking Therapeutics Inc (NASDAQ: VKTX) announced positive topline results from its Phase 2b trial of VK2809 in  
Via Benzinga
News headline image
Is Novo Nordisk Stock a Screaming Buy Right Now? ↗
The drugmaker's shares have crushed the broader markets over the past two years. Can it keep up this blistering momentum? 
Via The Motley Fool
News headline image
Why Top 1% Biotech Viking Therapeutics Is At The Brink Of A Record High ↗
The company is working on a treatment for nonalcoholic steatohepatitis, or NASH. 
Via Investor's Business Daily
News headline image
Why Viking Therapeutics Stock Is Trading Higher Tuesday ↗
Viking Therapeutics Inc (NASDAQ: VKTX) shares are trading higher Tuesday after the company announced positive top-line results from a Phase 
Via Benzinga
News headline image
Why Apellis Pharmaceuticals, TG Therapeutics, and Viking Therapeutics Were on the Move Today ↗
These three biotech stocks were on the volatile side today. 
Via The Motley Fool
News headline image
Eli Lilly's Diabetes Newcomer, Mounjaro, Just Blew Sales Projections Out Of The Water ↗
Mounjaro topped first-quarter sales expectations by more than $100 million. 
Via Investor's Business Daily
News headline image
Expert Ratings for Viking Therapeutics ↗
 
Via Benzinga
News headline image
Earnings Preview For Viking Therapeutics ↗
 
Via Benzinga
News headline image
Why Shares of Viking Therapeutics Skyrocketed This Week ↗
The clinical-stage stock nearly doubled in price. 
Via The Motley Fool
News headline image
Earnings Scheduled For April 26, 2023 ↗
Companies Reporting Before The Bell • Teck Resources (NYSE:TECK) is expected to report quarterly earnings at $1.36 per share on revenue of $3.11 billion. 
Via Benzinga
News headline image
3 Top Biotech Stocks Defying the Bear Market ↗
All three companies have therapies with strong sales potential. 
Via The Motley Fool
News headline image
Here are 2 Top Drug Makers Leading the Way in Weight Loss Drugs
The topic of weight loss drugs has been making recent headlines. The positive phase 1 clinical trial for Viking Therapeutics Inc. (NASDAQ: VKTX) GLP-1 treatme 
Via MarketBeat
News headline image
BTIG Maintains Buy Rating for Viking Therapeutics: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Novo Nordisk Surges To Another Record As Obesity Drugs Drive Higher Outlook ↗
Demand for Wegovy and Ozempic prompted Novo to raise its full-year outlook. 
Via Investor's Business Daily
News headline image
Red-Hot Obesity-Drug Maker Novo Nordisk Soars To Record On A $725 Million Deal ↗
Novo Nordisk is already a leader in obesity treatment with Saxenda and Wegovy. 
Via Investor's Business Daily
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
5 Best Stocks to Buy in April ↗
These powerful trends should yield stellar returns for investors in April and beyond. 
Via The Motley Fool
News headline image
Stock Market Rallies On Micron, Alibaba, Lululemon, Ebbing Bank Fears: Weekly Review ↗
The stock market rallied on ebbing bank fears and positive news from Micron, Alibaba and Lululemon Athletica. 
Via Investor's Business Daily
News headline image
RH, Semtech And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
U.S. stock futures traded higher this morning. Here are some big stocks recording losses in today’s pre-market trading session. Semtech Corporation (NASDAQ: SMTC) shares dipped 12.7% to $28.00 in... 
Via Benzinga
News headline image
Tesla, RH, Rumble, Stem, Viking Therapeutics: Why These 5 Stocks Are Drawing Investors' Attention Today ↗
 
Via Benzinga
News headline image
The Government Move That Could Drive Obesity Drugs — And Lilly, Novo Shares ↗
The decision from the WHO could further bolster use of Novo's Saxenda and Wegovy. 
Via Investor's Business Daily
< Previous 1 2
...
25 26 27 28 29 30 31 32 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.